Gastrazole Plus Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastric motility by enhancing gastric emptying and improving esophageal sphincter tone, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of these agents addresses both motility dysfunction and acid hypersecretion, making Gastrazole Plus effective in treating functional dyspepsia, GERD, and related upper gastrointestinal tract disorders. This combination is generally well tolerated; however, it should be used under medical supervision, particularly in patients with hepatic or renal impairment. Contraindications include hypersensitivity to any component of the formulation. Patients are advised to adhere to prescribed dosages and report any adverse reactions such as headache, dizziness, or allergic manifestations. Gastrazole Plus Capsule offers a comprehensive therapeutic approach to complex gastrointestinal conditions by combining prokinetic and acid-suppressive effects in a single dosage form.